US funds make $79m profit on investment in Irish rare disease drug developer, and could yet make another $62.5m
Amryt Pharma
Irish pharma company secures a 100%-plus premium for shareholders in deal to sell the business to bigger Italian rival
Eight-year old Amryt got EU approval last year for first treatment for rare genetic condition known as butterfly skin disease that primarily affects children
Drug firm says says delisting would enhance liquidity of trading
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
US Food and Drug Administration’s priority review can expedite review process to six months
Rolling submission began last summer
Placing of shares comes ahead of submission to regulators for approval of drug for rare condition
Results are a record for Dublin-based company, which has recently listed on Nasdaq
Swixx BioPharma will sell cholesterol drug across central and eastern Europe
Irish specialist in rare diseases says successful drug could tap $1bn market
Sectors include health and safety, pharma, crop protection and refrigeration
Warrants were issued in September as part of the company’s acquisition of Aegerion
YOU MAY ALSO LIKE...
Crosswords & puzzles to keep you challenged and entertained
Follow all the action from this year's championship
Start The Search For Your Next Job
Latest news and analysis on the battle to save the planet
A project examining attitudes about the future of Ireland
Weddings, Births, Deaths and other family notices